Navigation Links
Alliqua's SILVERSEAL Wound Outcome Data Presented at SAWC Fall Meeting
Date:10/1/2013

LANGHORNE, Pennsylvania, October 1, 2013 /PRNewswire/ --

In a scientific poster session at the Fall 2013 Symposium on Advanced Wound Care (SAWC) held September 27 to 29 in Las Vegas, Alliqua, Inc. (OTCQB: ALQA) ("Alliqua" or the "Company") shared the results from a post-marketing study to assess surgical wound outcomes in patients who have undergone foot and ankle surgery.

In the study, whose results were originally presented at the annual meeting of the American Orthopaedic Foot & Ankle Society in July, Alliqua's SilverSeal® dressing was shown to have a lower incidence of incision complications, including infection, and a greater reduction in scar length compared to standard petroleum-based dressing.

The data presented showed that of the nine incision complications observed, eight occurred in patients using the petroleum-based dressing and only one in those using SilverSeal (p=0.03). Length of post-surgical scarring was also reduced to a greater extent in patients using SilverSeal compared to those with a standard petroleum-based dressing.

The data was presented by Garrett M. Wobst, DPM, a Fellow at Coordinated Health in Bethlehem, PA and co-author of the study. Dr. Wobst stated, "In this study, the lower incidence of incision complications and the greater reduction in scar length demonstrate that the inherent properties of SilverSeal may aid in postsurgical incision healing versus conventional petrolatum dressing."

"A reduction in costs and surgical infections are top priorities in healthcare," added Dr. Philip Forman, Alliqua's Executive VP Clinical Affairs. "These data elucidate the extent to which SilverSeal dressings can be a key component in solving these issues. The results from this study are consistent with preliminary findings reported earlier this year and indicate that SilverSeal has the potential to not only improve post-surgical incision healing but also reduce healthcare expenditures that may be related to incision complications."

These results were summarized in an encore scientific poster titled "Utilization of Silver Hydrogel Sheet Dressing on Post-Surgical Incisions: A Pilot Study in Foot & Ankle Surgery" presented at the SAWC Fall meeting by Dr. Wobst. The poster number was CR-090.

About Alliqua, Inc.

Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing, and distribution of proprietary transdermal wound care and drug delivery technologies. Alliqua's technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.

Alliqua currently markets its new line of 510(k) FDA-approved hydrogel products for wound care under the SilverSeal® brand. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. Additionally, Alliqua's drug delivery platform, in combination with certain active pharmaceutical ingredients, can provide pharmaceutical companies with a transdermal technology to enhance patient compliance and potentially extend the patent life of valuable drug franchises.

For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K/A filed with the SEC on May 16, 2013, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Contact:

Brian M. Posner
Chief Financial Officer
+1(215)702-8550
bposner@alliqua.com

Investor Relations:
Dian Griesel Inc.
Cheryl Schneider
+1(212)825-3210
cschneider@dgicomm.com

Public Relations:
Dian Griesel Inc.
Susan Forman or Laura Radocaj
+1(212)825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com


'/>"/>
SOURCE Alliqua, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. US Bioactive Wound Care Market 2016: Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2012-2016, Report Available Online by Researchmoz.us
2. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
3. Elsevier Announces the Launch of a New Journal: Wound Medicine
4. Innovative Therapies Inc (ITI) Announces New Executive Management Team of the Wound Care Therapy Division and New User Friendly Website
5. Pinnaclife Animal Health Features Seal N Heal Wound Shield in New Veterinary Dermatologist Tested and Approved Product Line!
6. Synedgen’s Synoplex® Receives FDA Indexing for Use in the Treatment of Chronic Wounds in Pachyderms
7. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
8. Arteriocyte Receives FDA Approval to Initiate Compartment Syndrome Trial for Amputation Prevention Focused on Wounded Warriors
9. CE Mark Granted for Wound Spray Based on Sangui Patent
10. Healing the iPhones wounds
11. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):